B7 homolog 3 (B7-H3)

Where the papers sit

21 papers from the last 6 months study B7 homolog 3 (B7-H3) directly · updated from PubMed 7 Oct 2026

• Solid Tumor Immunotherapy and Imaging

  Engineered B7-H3 CAR-T cells are being optimized for solid tumors through fully human receptors, EGFR T-cell engagers, p40 engineering and tumor sensitization. Radiotherapy and tumor-microenvironment remodeling are used to improve activity against radio-resistant disease, including glioblastoma and neuroblastoma. Parallel imaging efforts use antibody-fluorophore conjugates, 68Ga bicyclic peptides and longitudinal biodistribution profiling to guide surgery and delivery. The shared direction is tighter coupling of therapeutic engineering with target visualization, but evidence remains preclinical.

  7 papers · 33.3%

• Engineered Cancer Immunotherapy

  Immune escape is being tackled with checkpoint disruption, CAR-based effectors and rational multimodal combinations. CD276/SPARC signaling and TIGIT-CD155 emerge as mechanisms that can weaken immune control or CAR-T function, while GPC3 CAR-NK cells plus enoblituzumab illustrate combination targeting in liver cancer. Binder discovery is shifting toward AI-designed minibinders validated by mRNA or yeast display. The field remains preclinical and spans AML, hepatocellular carcinoma and pediatric solid tumors rather than one settled regimen.

  6 papers · 28.6%

• Prostate Cancer Targeting

  Androgen-regulated B7-H3 expression is being developed as both a prognostic marker and a therapeutic entry point in prostate cancer. Tissue and gene-expression studies support broad expression and combinatorial treatment strategies, while vobramitamab duocarmazine provides early clinical testing of antibody-drug conjugate therapy. Extracellular-vesicle proteomics is adding biomarker approaches for 177Lu-PSMA-617 response. Whether B7-H3 selection improves outcomes, and how it relates to PSMA-directed treatment, remains open.

  5 papers · 23.8%

• ADC Therapy in Solid Tumors

  ADC development is moving toward B7-H3-directed treatment of small cell lung cancer and other solid tumors, with expression profiling used to refine target selection. Preclinical work spans patient-derived xenografts, metastasis and the tumor microenvironment, while triple-negative breast cancer motivates combination strategies. The main question is whether strong target expression translates into durable tumor control. Clinical validation remains less mature than the candidate pipeline.

  3 papers · 14.3%